China Nuokang Bio-Pharmaceutical Inc. to Report Second Quarter 2012 Financial Results

| Source: China Nuokang Bio-Pharmaceutical Inc.

BEIJING, Aug. 1, 2012 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company plans to release second quarter 2012 financial results on Wednesday, August 22, 2012 after the market closes.

The Company will hold a conference call at 8:00 a.m. ET on Thursday, August 23, 2012 to discuss second quarter 2012 results. Listeners may access the call by dialing:

United States toll free: 1-855-500-8701
China toll free: 400-1200654
Hong Kong toll free: 800-903737 
United Kingdom toll free: 0800-0159724 
International: 65-6723-9385 
Conference ID: 14787970

A telephone replay will become available beginning two hours after the conclusion of the call and will remain available through September 6, 2012. Listeners may access the replay by dialing:

United States toll free:  1-866-214-5335 
International:  1-718-354-1232
Conference ID: 14787970

A webcast will also be available through the Company's website

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 4,200 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share; Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant product that addresses diabetic neuropathy. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit for more information.

China Nuokang Bio-Pharmaceutical Inc.
Mr. Steven Duan
Vice President of Investor Relations

ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516 or (646) 405-5180